Search Results

You are looking at 71 - 80 of 470 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass

rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. Adjuvant Therapy for Stage II Disease The panel discussed the impact of adjuvant chemotherapy on

Full access

Lingling Du and Andrea Wang-Gillam

Neoadjuvant Approach Phase III trials have demonstrated a clear survival benefit with adjuvant chemotherapy. 5 , 7 Multiple studies examined neoadjuvant therapy as an alternative to the traditional adjuvant approach. Neoadjuvant therapy offers patients the

Full access

Wells A. Messersmith

NCCN Guidelines, despite not being FDA-approved for this indication, because the data are “so compelling,” he added. Dr. Messersmith focused mainly on 2 combination therapies for adjuvant chemotherapy for resected (primary) colon cancer: FOLFOX

Full access

Natasha Satkunam, Xuejiao Wei, James J. Biagi, Sulaiman Nanji, and Christopher M. Booth

Background Adjuvant chemotherapy (ACT) with 5-fluorouracil (FU) has been the standard of care for stage III or high-risk stage II colon cancer since the 1990s. 1 This treatment is based on a series of randomized clinical trials (RCTs) showing

Full access

A. Dimitrios Colevas, Sue S. Yom, David G. Pfister, Sharon Spencer, David Adelstein, Douglas Adkins, David M. Brizel, Barbara Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, David W. Eisele, Moon Fenton, Robert L. Foote, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Ellie Maghami, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, James Rocco, Cristina P. Rodriguez, Jatin P. Shah, Randal S. Weber, Matthew Witek, Frank Worden, Weining Zhen, Jennifer L. Burns, and Susan D. Darlow

in any form without the express written permission of NCCN®. randomized trial from China comparing concurrent cisplatin/RT with (or without) adjuvant cisplatin/5-FU showed that adjuvant chemotherapy did not significantly improve survival following CRT

Full access

Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Courtney Smith

of adjuvant systemic chemotherapy in invasive bladder cancer. Studies have shown that adjuvant chemotherapy may delay recurrences and improve OS, 41 – 43 but no randomized comparisons of adequate sample size have definitively shown a survival benefit

Full access

Robert E. Smith Jr.

://www.nccn.org . Accessed May 23, 2006 . 4. Kim ES Vokes EE Kies MS . Cetuximab in cancers of the lung and head & neck . Semin Oncol 2004 ; 31 ( suppl 1 ): 61 – 67 . 5. Hryniuk W Levine MN . Analysis of dose intensity for adjuvant chemotherapy

Full access

/18/14 NCCN Guidelines® Insights: Metastatic Colon Cancer, Version 3.2013 Expiration Date: 2/18/14 Using Multigene Tests to Select Treatment for Early-Stage Breast Cancer Expiration Date: 2/18/14 CASE REPORT: Adjuvant Chemotherapy Decisions in Clinical

Full access

Early-Stage Breast Cancer Expiration Date: 2/18/14 CASE REPORT: Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations

Full access

Lindsay A. Gil, Mariam F. Eskander, Samilia Obeng-Gyasi, Bridget A. Oppong, Yaming Li, and Allan Tsung

receiving fragmented care (treatment at multiple facilities) and its implications on receipt of GCC. Methods: The National Cancer Database (NCDB) 2006-2016 was queried for patients with pancreatic adenocarcinoma who underwent resection and adjuvant